-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – DZD-8586 in Refractory Chronic Lymphocytic Leukemia (CLL)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - DZD-8586 in Refractory Chronic Lymphocytic Leukemia (CLL) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. DZD-8586 in Refractory Chronic Lymphocytic Leukemia (CLL) Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Lisocabtagene Maraleucel in Primary CNS Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Lisocabtagene Maraleucel in Primary CNS Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Lisocabtagene Maraleucel in Primary CNS Lymphoma Drug Details: Lisocabtagene...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Durvalumab in Endometrial Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Durvalumab in Endometrial Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Durvalumab in Endometrial Cancer Drug Details: Durvalumab (MEDI-4736, Imfinzi, Fidursi, Imfinzio)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Durvalumab in Fallopian Tube Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Durvalumab in Fallopian Tube Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Durvalumab in Fallopian Tube Cancer Drug Details: Durvalumab (MEDI-4736, Imfinzi,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Durvalumab in Peritoneal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Durvalumab in Peritoneal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Durvalumab in Peritoneal Cancer Drug Details: Durvalumab (MEDI-4736, Imfinzi, Fidursi, Imfinzio)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Abemaciclib in Malignant Mesothelioma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Abemaciclib in Malignant Mesothelioma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Abemaciclib in Malignant Mesothelioma Drug Details: Abemaciclib (Verzenio / Verzenios /...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Durvalumab in Pancreatic Ductal Adenocarcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Durvalumab in Pancreatic Ductal Adenocarcinoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Durvalumab in Pancreatic Ductal Adenocarcinoma Drug Details: Durvalumab (MEDI-4736, Imfinzi,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Dexamethasone Sodium Phosphate in Prostate Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Dexamethasone Sodium Phosphate in Prostate Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Dexamethasone Sodium Phosphate in Prostate Cancer Drug Details: Dexamethasone...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Dexamethasone Sodium Phosphate in Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Dexamethasone Sodium Phosphate in Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Dexamethasone Sodium Phosphate in Hodgkin Lymphoma...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Dexamethasone Sodium Phosphate in Colon Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Dexamethasone Sodium Phosphate in Colon Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Dexamethasone Sodium Phosphate in Colon Cancer Drug Details: Dexamethasone...